Litai Intelligence Pharmaceutical, a company at the forefront of AI-driven peptide drug innovation, boasts a multidisciplinary core team and is guided by a seasoned advisory panel. The company recently proudly announced the successful closure of a seed funding round, raising nearly 50 million yuan. The roster of investors includes prominent names such as iFLYTEK Venture Capital, L2F Lightsource Entrepreneur Fund, and other esteemed industry participants, with Lightsource Capital acting as the exclusive financial advisor.

The proceeds from this funding round will be strategically allocated to computing power leasing, core drug pipeline R&D, patent filings, talent acquisition, and the day-to-day operations of the company. Litai Intelligence Pharmaceutical operates on a 'platform + pipeline' dual-engine model, leveraging platform collaborations and joint R&D efforts to monetize its technology in the short term. The company has already forged partnerships with several listed pharmaceutical companies, biotech firms, top-tier hospitals, and national key laboratories, with some projects now in the preclinical research phase.

Looking ahead, Litai Intelligence Pharmaceutical will concentrate on advancing its proprietary new drug pipeline, with a strategic focus on three high-value therapeutic areas: oncology, autoimmune diseases, and metabolism. The company is dedicated to becoming a leading AI-native pharmaceutical enterprise, ultimately delivering innovative peptide drugs to patients in need. The founder of Litai Intelligence Pharmaceutical, along with key leaders from the investors and financial advisor, all share a positive outlook on the company's growth prospects in the realm of AI-powered peptide drug innovation.